Zerbino D D, Lukasevich L L, Bilynskaia O A
Arkh Patol. 1990;52(4):65-9.
Lupus anticoagulant was determined in lupus erythematosus as an antibody inhibiting prothrombin activation in phospholipid coagulation tests without specific suppression of any coagulation factors. The available information concerning properties and mechanisms of action of lupus anticoagulant are rather controversial as there exist a group of similar coagulation inhibitors that represent antiphospholipid antibodies. In spite of a considerable increase of a coagulation test time prothrombin time, partial thromboplastin time, the presence of the lupus anticoagulant is rarely followed by haemorrhagic diathesis. On the contrary, recurring thromboembolic complications, pathology of gestation are observed in patients with this or other antibodies against phospholipids. The appearance of the antiphospholipid antibodies is described in infections, haematological processes, systemic vasculitis, tumours, may be provoked by a long use of some medicinal preparations. Circulation of the lupus coagulant and other antibodies against phospholipids is of a chronic type while in infections diseases it is of an acute transitory character.
狼疮抗凝物是在红斑狼疮中测定的一种抗体，它在磷脂凝血试验中抑制凝血酶原激活，而不特异性抑制任何凝血因子。关于狼疮抗凝物的性质和作用机制的现有信息存在相当大的争议，因为存在一组代表抗磷脂抗体的类似凝血抑制剂。尽管凝血试验时间（凝血酶原时间、部分凝血活酶时间）显著延长，但狼疮抗凝物的存在很少伴有出血素质。相反，患有这种或其他抗磷脂抗体的患者会出现反复的血栓栓塞并发症和妊娠病理。抗磷脂抗体在感染、血液学过程、系统性血管炎、肿瘤中出现，可能由长期使用某些药物制剂引起。狼疮抗凝物和其他抗磷脂抗体的循环是慢性的，而在感染性疾病中则是急性短暂性的。
